ce-mark
(2)Bing Li
Bing Li is the CEO and co-founder of Intalight, an ophthalmic imaging company behind the DREAM OCT swept-source platform. Founded in 2014 by a group of scientists and Silicon Valley industry veterans, Intalight built one of the first swept-source OCT devices in 2019 and has since powered more than 170 peer-reviewed retinal-imaging studies. Trained as an engineer and applied mathematician, Li moved from the auto and semiconductor industries into eye care, betting that faster, deeper, wider retinal scans would change how clinicians see inside the eye. In May 2025 the company won CE Mark clearance to sell DREAM OCT across the European Union, with FDA review pending in the United States.
Martin Cannon
Martin Cannon is the founder and former president and CEO of Hemanext, the Lexington, Massachusetts company that turned an unproven idea - storing blood with the oxygen taken out - into an FDA-authorized, CE-marked medical device. Starting in the late 1990s with intellectual property licensed from Los Alamos National Laboratory and a handful of employees, he spent more than two decades building Hemanext into a recognized name in red blood cell transfusion, raising over $150 million in equity and NIH funding and securing more than 200 patents along the way. He retired in September 2023, handing the CEO role to longtime CTO Andrew Dunham, and now advises early-stage companies and mentors entrepreneurs.